Exosome Technologies Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players

Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players

Summary

GBI Research's latest report, Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players, explores the application of exosome technologies within the pharmaceutical and healthcare industries. Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine and cerebrospinal fluid as well as in in vitro cell culture.

These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right. Research within this area remains in the nascent stages, although a number of clinical trials have been registered within the field. Exosomes have several diverse therapeutic applications, largely centering on stem cell and gene therapy. Exosomes have been identified as endogenous carriers of RNA within the body, allowing for the intercellular transportation of genetic material to target cells.

Get Sample Copy https://www.reportsweb.com/inquiry&RW00012325988/sample

As such, developers have worked to engineer exosomes for the delivery of therapeutic miRNA and siRNA-based gene therapies. As RNA is highly unstable within the body, a number of different biologic vector systems have been developed to enhance their transport within the circulation, including viruses and liposomes. Similarly, exosomes derived from stem cells have also been identified for their therapeutic applications, particularly in the treatment of cancer and cardiovascular disease. Exosome technologies offer several advantages over existing biologic-based drug delivery systems.

They have a long circulatory half-life as a result of their high stability and ability to avoid breakdown by the mononuclear phagocyte system and reticuloendothelial systems. Moreover, exosomes have several functional properties that favor their use in therapeutic delivery. Exosomes can be engineered to incorporate targeting ligands, allowing them to deliver cargo selectively to cells. Their small size allows them to penetrate the blood-brain barrier for the delivery of central nervous system therapies, whereas in cancer they can accumulate within the tumor via enhanced permeability and retention effects.

Finally, clinical trials have shown relatively large-scale production to be possible and indicate that exosome therapies can be safely administered to humans. Additionally, exosomes are being investigated for their potential as prognostic and diagnostic biomarkers for several different disease indications. Exosomes make good candidates for biomarker research because of two unique characteristics: their presence in various accessible bodily fluids, and their resemblance to their parent cells of origin. R&D in exosome technologies has increased markedly in recent years. This report provides detailed information on the various healthcare applications of exosomes, and assesses the pipeline, clinical trial and company landscapes.

Make an enquiry: https://www.reportsweb.com/inquiry&RW00012325988/buying

Scope

-What are the features of the exosome lifecycle-
-How are therapeutic exosomes prepared-
-How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area-
-Which companies are investing in exosome technologies-
-How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors-

Reasons to buy

-Develop a comprehensive understanding of exosome technologies and their potential for use within the healthcare sector.
-Analyze the pipeline landscape and gain insight into the key companies investing in exosomes technologies.
-Identify trends in interventional and observational clinical trials relevant to exosomes.

Table of Content:

1 List of Tables
2 Exosomes in Healthcare 8
3 Assessment of Pipeline Product Innovation 36
4 Assessment of Clinical Trial Landscape 48
5 Company Analysis and Positioning 67
5.1 Company Profiles 67
5.1.1 Capricor Therapeutics Inc. 67
5.1.2 Evox Therapeutics Ltd 72
5.1.3 ReNeuron Group Plc 73
5.1.4 Stem Cell Medicine Ltd 77
5.1.5 Tavec Inc. 78
5.1.6 Codiak Biosciences Inc. 80
5.1.7 Therapeutic Solutions International Inc. 81
5.1.8 ArunA Biomedical Inc. 83
5.1.9 Ciloa 85
6 Appendix 86
6.1 References 86
6.2 Abbreviations 91
6.3 About GBI Research 93
6.4 Disclaimer 93

Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

USA

This release was published on openPR.